---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000076"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:04:11.216028+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board

## Summary
- Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.
- Appointed to Science and Technology Committee of the Board effective July 8, 2025.
- Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.
- Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata.

## SEC filing metadata
- accession: 0001439222-25-000076
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/0001439222-25-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/agio-20250703.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000076
- JSON: https://secwatch.observer/filing/0001439222-25-000076.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.